Intellia Therapeutics Inc (NASDAQ: NTLA) shares are tumbling in after-hours trading on Wednesday after the company announced ...

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z. ・The ...

Intellia Therapeutics temporarily paused patient dosing and screening for trials of its nex-z drug after a patient dosed with the drug reported signs of liver injury. The drug is intended to treat ...

Intellia Therapeutics stock was down 44.06% in pre-market trading on Monday, following a 1.12% drop on Friday. The stock was ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

This is a preview. Log in through your library . Abstract The relationship between circulating total bilirubin and incident non-alcoholic fatty liver disease (NAFLD) is uncertain. We aimed to assess ...

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...